Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Viridian Therapeutics, Inc. (VRDN : NSDQ)

• Company Description    Viridian Therapeutics Inc. is a biotechnology company advancing new treatments for patients suffering from serious diseases. The company's program includes VRDN-001, which is in clinical stage. Viridian Therapeutics Inc., formerly known as miRagen Therapeutics Inc., is based in BOULDER, Colo. Number of Employees: 50

• Price / Volume Information    Yesterday's Closing Price: $13.01 Daily Weekly Monthly 20 Day Moving Average: 266,206 shares Shares Outstanding: 27.93 (millions) Market Capitalization: $363.34 (millions) Beta: 1.12 52 Week High: $22.00 52 Week Low: $9.47 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -16.98% -6.48% 12 Week -30.61% -23.71% Year To Date -34.19% -19.59%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 221 CRESCENT STREET SUITE 401 - WALTHAM,MA 02453 USA ph: 617-272-4600 fax: 760-537-4101 daniel@lifesciadvisors.com http://www.viridiantherapeutics.com

• General Corporate Information    Officers Jonathan Violin - President; Chief Executive Officer and Director Tomas Kiselak - Chairman Kristian Humer - Chief Financial Officer Peter Harwin - Director Arlene Morris - Director Peer Information Viridian Therapeutics, Inc. (CORR.) Viridian Therapeutics, Inc. (RSPI) Viridian Therapeutics, Inc. (CGXP) Viridian Therapeutics, Inc. (BGEN) Viridian Therapeutics, Inc. (GTBP) Viridian Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 92790C104 SIC: 8071 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/10/22 Share - Related Items Shares Outstanding: 27.93 Most Recent Split Date: 11.00 (0.07:1) Beta: 1.12 Market Capitalization: $363.34 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.83 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.75 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/10/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 6.48 Price/Cash Flow: - Price / Sales: 210.26 EPS Growth vs. Year Ago Period: 66.32% vs. Previous Quarter: 25.76% Sales Growth vs. Year Ago Period: -85.11% vs. Previous Quarter: 0.93% ROE 03/31/22 - -360.68 12/31/21 - - 09/30/21 - - ROA 03/31/22 - -47.72 12/31/21 - -47.70 09/30/21 - -48.09 Current Ratio 03/31/22 - 12.47 12/31/21 - 14.68 09/30/21 - 15.20 Quick Ratio 03/31/22 - - 12/31/21 - 14.68 09/30/21 - 15.20 Operating Margin 03/31/22 - -5,014.24 12/31/21 - -2,680.16 09/30/21 - -2,545.42 Net Margin 03/31/22 - -5,014.24 12/31/21 - -2,680.16 09/30/21 - -5,037.78 Pre-Tax Margin 03/31/22 - -5,014.24 12/31/21 - -2,680.16 09/30/21 - -5,037.78 Book Value 03/31/22 - 1.95 12/31/21 - 2.48 09/30/21 - 2.23 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©